Trials / Completed
CompletedNCT04679948
A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood
The Effect of Multiple Doses of BI 730357 on the Single Dose Pharmacokinetics of Caffeine, Warfarin, Omeprazole and Midazolam Administered Orally as a Cocktail in Healthy Subjects (an Open-label, Two-period Fixed Sequence Design Trial)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The trial will be performed to assess the influence of BI 730357 on the pharmacokinetics of caffeine, warfarin, omeprazole and midazolam.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Percoffedrinol® | Tablet |
| DRUG | Coumadin® | Tablet |
| DRUG | Antra MUPS® | Gastro-resistant tablet |
| DRUG | Midazolam-ratiopharm® | Oral solution |
| DRUG | BI 730357 | Film-coated tablet |
Timeline
- Start date
- 2020-12-21
- Primary completion
- 2021-03-17
- Completion
- 2021-03-17
- First posted
- 2020-12-22
- Last updated
- 2023-08-14
- Results posted
- 2023-07-17
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04679948. Inclusion in this directory is not an endorsement.